SHARONBIO

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on September 11, 2020.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Pursuant to Clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Free Press Journal and Navshakti relating to the consideration and approval of Unaudited financial results of the Company for the quarter ended June 30, 2020.Kindly take the same on your records.'.

The Exchange has sought clarification from Sharon Bio-Medicine Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not signed by authorized signatory/ies The response of the Company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India (Depositories and participants) Regulations 2018'.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on Jun 26, 2020.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended March 31, 2020.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Disclosure of material impact of COVID 19 pandemic'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018'.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 that pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company by Designated Persons and their immediate relatives shall remain closed from April 1, 2020 till Forty Eight (48) hours after the declaration of Audited Financial Results of the Company for the year ended March 31, 2020. Currently, the trading is temporarily suspended for capital reduc

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Dear Sir/Madam,Sub: Newspaper Publication of Unaudited financial results Pursuant to Regulation 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Free Press Journal and Navshakti on the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2019.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on February 12, 2020.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended December 31, 2019.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Dear Sir/Madam,Sub: Publication for Intimation of Unaudited financial results Pursuant to Clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Free Press Journal and Navshakti relating to the consideration and approval of Unaudited financial results of the Company for the quarter and nine months ended December 31, 2019.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018'.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Newspaper Publication of Unaudited Financial Results '.

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on November 14, 2019.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended September 30, 2019.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Publication for Intimation of Unaudited financial results '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Intimation/ Disclosure pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 '.

Sharon Bio-Medicine Limited has informed the Exchange regarding ''In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, we are forwarding herewith a copy of the Certificate dated 16th October, 2019, received from M/s Link Intime (India) Pvt. Ltd., the Registrar and Share Transfer Agent of the Company, for the quarter ended 30th September, 2019.''.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Extension application for conducting Annual General Meeting (AGM) '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Newspaper Publication of Unaudited financial results for the quarter ended June 30, 2019.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on August 14, 2019.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Publication for intimation of Unaudited financial results '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 received from M/s. Link Intime India Private Limited, the Registrar and Share Transfer Agent of our Company for the quarter ended June 30, 2019'.

Sharon Bio-Medicine Limited has informed the Exchange regarding Submission of disclosure on Related Party Transactions.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company by Designated Persons and their immediate relatives shall remain closed from July 1, 2019 till Forty Eight (48) hours after the declaration of Unaudited Financial Results of the Company for the Quarter ended June 30, 2019.

The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.

The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Copy of advertisement published in newspaper '.

Sharon Bio-Medicine Limited has informed the Exchange regarding Board meeting held on May 24, 2019.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.

SBICAP Trustee Company Ltd has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Intimation for consideration and declaration of Audited financial results for the year ended March 31, 2019. '.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Certificate under Regulation 74 (5) of Securities and Exchange Board of India(Depositories and Participants) Regulations 2018'.

Sharon Bio-Medicine Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

SHARONBIO: Members of the Exchange are hereby informed that the trading in Equity Shares of Sharon Bio-Medicine Limited shall be suspended w.e.f. March 29, 2019 (i.e. closing hours of trading on March 28, 2019) on account of Reduction of Share Capital

Sharon Bio-Medicine Limited has informed the Exchange that the Company has fixed Record Date as April 2, 2019 for the purpose of Reduction of Equity Share Capital of the Company pursuant to theResolution Plan approved by the Hon'ble National Company Law Tribunal

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Withdrawal of Closure Notice for the manufacturing activity of API Plant'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Update on USFDA inspection at our API facility.'.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Recovery notice from the Commissioner of State Tax for the year 2011-12 and 2015-16'.

Sharon Bio-Medicine Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.

:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 28-Jan-2019, regarding 'Closure of operations of API plant '.". On basis of above the Company is required to clarify following: 1. Date of closure or estimated time of closure;2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year;The response of the Company is attached.

SHARONBIO:The Exchange has sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 28-Jan-2019, regarding 'Closure of operations of API plant '.". On basis of above the Company is required to clarify following: 1. Date of closure or estimated time of closure;2. Amount & percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year;The response of the Company is awaited.

SHARONBIO:The Exchange had sought clarification from Sharon Bio-Medicine Limited with respect to announcement dated 09-Jan-2019, regarding that�� Ms. Komal Mota has been appointed as a Company Secretary & Compliance Officer w.e.f�� January 08, 2019." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is enclosed.Ms. Komal Mota is a qualified Company Secretary and LLB having more than 4 years of experience and worked with Listed and Private Companies.

Sharon Bio-Medicine Limited has informed the Exchange regarding 'Closure of operations of API plant '.